iTRIALSPACE: Programmable Virtual Lesion Trials for Controlled Evaluation of Lung CT Models

We introduce iTRIALSPACE, a programmable evaluation framework for controlled assessment of lung CT models. Standard benchmarks are static retrospective collections that entangle lesion size, lobe prevalence, anatomy, and acquisition context, making it difficult to determine what structurally drives model accuracy. iTRIALSPACE addresses this limitation by composing real clinical CTs and lesion profiles into controlled virtual lesion trials through a four-stage pipeline: multidataset nodule profiling, explicit trial specification, anatomy-aware mask insertion, and ControlNet-conditioned CT synthesis. The framework is built on a unified 54-attribute nodule-profile dataset spanning 13,140 annotated nodules from seven public CT sources and instantiated as 13 trial modes. We evaluate iTRIALSPACE in a 55,469-sample Virtual Lesion Study spanning three medical VLMs, four spatialguidance conditions, and three clinical tasks. Across all 13 modes, the synthetic substrate remains within the real-to-real FID baseline, and synthetic performance rankings transfer strongly to real clinical data ($ρ$ = 0.93, p < 10$^{-15}$). Controlled trial modes expose findings unavailable to fixed-distribution benchmarks, including shortcut-driven size prediction collapse under lobe-equalized sampling and hostto-donor variance ratios of 8.9x and 3.3x in twin-cross analysis. These results position iTRIALSPACE as an auditable evaluation infrastructure for controlled, falsifiable testing beyond static retrospective benchmarks.

A Synopsis of Stent Graft Technology Development

Coronary artery disease (CAD) is a leading cause of death worldwide. Treatments have evolved, with stenting becoming the primary approach over bypass surgery. This article reviews the evolution of coronary stent technology, starting from the first angioplasty in 1977. Pioneers like Forssmann, Dotter, and Gruentzig established the foundation. The late 1980s saw the introduction of bare metal stents (BMS) to address angioplasty limitations. However, BMS had issues, leading to the development of first-generation drug-eluting stents (DES) in the early 2000s, which reduced restenosis but had safety concerns. Subsequent innovations introduced second-generation DES with better results and the latest bioresorbable vascular scaffolds (BVS) that dissolve over time. Clinical trials have been crucial in validating each stent's effectiveness. Despite progress, challenges remain in stent selection, approval processes, and minimizing risks. The future may see personalized stenting based on patient needs, highlighting the significant advancements in stent technology and its impact on patient care.